Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Transition Therapeutics Inc Announces Enrollment Of Patient In Phase 2 Study Of ELND005 For Treatment Of Agitation/Aggression in Patients with Alzheimer's Disease


Wednesday, 28 Nov 2012 08:30am EST 

Transition Therapeutics Inc announced its licensing partner, Elan Corporation, plc (Elan) has enrolled the first patient in a Phase 2 study of ELND005 (Study AG201) for the treatment of agitation/aggression in patients with moderate to severe Alzheimer's disease (AD). The objectives of Study AG201 are to evaluate the efficacy, safety and tolerability of ELND005 over 12 weeks of treatment in patients with moderate to severe AD, who are experiencing at least moderate levels of agitation/aggression. The study is expected to enroll approximately 400 patients at multiple sites in the US, Canada and potentially other selected regions. In the Phase 2 AD Study (AD201), ELND005 appeared to decrease the emergence and severity of specific neuropsychiatric symptoms, an effect which seemed to correlate with drug exposure for some symptoms. ELND005 also led to a sustained reduction of brain Myo-inositol levels that are thought to play a role in phospho-inositol signaling pathways and synaptic activity. 

Company Quote

7.69
-0.16 -2.04%
19 Sep 2014